1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Robert Zaczek new CSO at NeurOp

 
• By Gemma Sharman

Atlanta-based biopharmaceutical company NeurOp, which specialises in developing new medicines for central nervous system disorders, has appointed Dr Robert Zaczek chief scientific officer. Dr Zaczek most recently served as executive director of psychiatry drug discovery at Bristol-Myers Squibb, during which time he headed the joint research team that currently collaborates with NeurOp on its depression and neuropathic pain programmes.

Atlanta-based biopharmaceutical company NeurOp, which specialises in developing new medicines for central nervous system disorders, has appointed Dr Robert Zaczek chief scientific officer. Dr Zaczek most recently served as executive director of psychiatry drug discovery at Bristol-Myers Squibb, during which time he headed the joint research team that currently collaborates with NeurOp on its depression and neuropathic pain programmes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.